Conditions · Pancreatic cancer
Pancreatic cancer — clinical trials in United States
30 open options
- TRIALPHASE1 / PHASE2RECRUITING
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Biospecimen Collection · Computed Tomography · Core Biopsy — 1 site
- TRIALPHASE2RECRUITING
EUS-RFA PANCARDINAL-1 Trial
Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) · Neoadjuvant Chemotherapy (NAC) — 1 site
- TRIALNARECRUITING
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Palliative radiotherapy — 7 sites
- TRIALNARECRUITING
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
Daily Adaptive External Beam Radiation Therapy — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Gemcitabine · Nab paclitaxel · Erlotinib — 1 site
- TRIALNARECRUITING
MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer
Electronic Health Record Review · Smartphone Application-based Intervention · Survey Administration — 1 site
- TRIALPHASE2RECRUITING
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
Nab-paclitaxel + Gemcitabine · modified FOLFIRINOX (mFOLFIRINOX) — 1 site
- TRIALPHASE2RECRUITING
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Riluzole · Placebo — 1 site
- TRIALNANOT_YET_RECRUITING
SURGIMEDIA: Utilization of Multimedia for Enhanced Surgical Consent
Standard Informed Consent · Multimedia Video - Based Informed Consent — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
Directional Brachytherapy Source Implant — 6 sites
- TRIALPHASE2NOT_YET_RECRUITING
SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial
Biospecimen Collection · Computed Tomography · Electronic Health Record Review — 1 site
- TRIALNARECRUITING
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence
Treatment Plan — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
AGEN2373 · Balstilimab · Cyclophosphamide — 1 site
- TRIALPHASE1RECRUITING
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NT-112: Autologous, engineered T Cells targeting KRAS G12D · AZD0240: Autologous, engineered T Cells targeting KRAS G12D — 18 sites
- TRIALPHASE1RECRUITING
Autologous CAR-T Cells Targeting B7-H3 in PDAC
iC9-CAR.B7-H3 T cell infusion — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
AMXI-5001:Dose Escalation Phase I · AMXI-5001:Dose Expansion Phase II — 4 sites
- TRIALPHASE1 / PHASE2RECRUITING
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
LUM015 · LUM 2.6 Imaging Device — 1 site
- TRIALPHASE1RECRUITING
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
Samuraciclib · Computed Tomography · Endoscopic Ultrasound Biopsy — 1 site
- TRIALPHASE3RECRUITING
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Setidegrasib · Oxaliplatin · Leucovorin — 48 sites
- TRIALPHASE1 / PHASE2RECRUITING
A 2-part Phase 1/2 Open-label Trial on ODM-212
ODM-212 · Ipilimumab and nivolumab · Gemcitabine and nab-paclitaxel — 2 sites
- TRIALPHASE1RECRUITING
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
ASP2138 · Oxaliplatin · Leucovorin — 3 sites
- TRIALPHASE2RECRUITING
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Autogene cevumeran · Atezolizumab · mFOLFIRINOX — 89 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Evofosfamide · Zalifrelimab · Balstilimab — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BNT329 · CA19-9-targeting monoclonal antibody — 16 sites
- TRIALNANOT_YET_RECRUITING
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
Actigraphy · Online Mindfulness Meditation · Smartphone Application-based Intervention — 1 site
- TRIALNARECRUITING
DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer
Point-of-care Portable Perfusion Phantom (P4) — 2 sites
- TRIALPHASE1RECRUITING
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
XL309 · Olaparib — 16 sites
- TRIALNARECRUITING
Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens
ARTIDIS ART-1 Device — 1 site
- TRIALPHASE1RECRUITING
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Metarrestin — 2 sites
- TRIALPHASE3RECRUITING
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Kinisoquin™ · Placebo — 3 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.